Thursday, 22 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 24, 2026

Debt Spirals vs. AI Factories: The Great Macro Divide of 2026

View original at finance.yahoo.com
Debt Spirals vs…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Global debt to GDP is 310%. The spending problem at the federal, state, local level, the spending problem in every country... ultimately breaks.

    60% confidence
  • America's energy independence and massive technological lead mean it is winning the most critical race in history, warranting a bullish investment stance

    60% confidence
  • The tech industry's massive AI infrastructure buildout is sustainable only if bond markets stabilize; rising Treasury yields and global debt-to-GDP of 310% threaten financing costs for unprecedented capex spending

    60% confidence
  • The appropriate response to macro uncertainty is to narrow the portfolio down to a few high-conviction names rather than taking a strong directional macro bet

    60% confidence
  • Alphabet raised full-year capex guidance to $180-$190B

    60% confidence
  • Bond markets are pricing the sovereign debt problem, evidenced by the 30-year Treasury at 5.2% and the potential unwind of the Japanese carry trade as a possible catalyst

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com